array(40) {
  [0]=>
  string(4) "9529"
  ["article_id"]=>
  string(4) "9529"
  [1]=>
  string(73) "Breakthrough delivery system could transform Alzheimer’s treatment"
  ["article_title"]=>
  string(73) "Breakthrough delivery system could transform Alzheimer’s treatment"
  [2]=>
  string(150) "In a groundbreaking development, a team of biochemical engineers from South Korea has unveiled a new exosome-based delivery system, termed MAPLEX, tha"
  ["short_description"]=>
  string(150) "In a groundbreaking development, a team of biochemical engineers from South Korea has unveiled a new exosome-based delivery system, termed MAPLEX, tha"
  [3]=>
  string(243) "In a groundbreaking development, a team of biochemical engineers from South Korea has unveiled a new exosome-based delivery system, termed MAPLEX, that holds the potential to transform treatments for various diseases, including Alzheimerâs."
  ["description"]=>
  string(243) "In a groundbreaking development, a team of biochemical engineers from South Korea has unveiled a new exosome-based delivery system, termed MAPLEX, that holds the potential to transform treatments for various diseases, including Alzheimerâs."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(173) "https://www.biopharma-reporter.com/Article/2024/08/21/Korean-scientists-develop-novel-MAPLEX-system-for-precision-therapy?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(173) "https://www.biopharma-reporter.com/Article/2024/08/21/Korean-scientists-develop-novel-MAPLEX-system-for-precision-therapy?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-08-21 17:59:00"
  ["add_date"]=>
  string(19) "2024-08-21 17:59:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:26:38"
  ["create_at"]=>
  string(19) "2024-08-24 15:26:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9434"
  ["article_id"]=>
  string(4) "9434"
  [1]=>
  string(72) "As the rush toward AI in healthcare continues, explainability is crucial"
  ["article_title"]=>
  string(72) "As the rush toward AI in healthcare continues, explainability is crucial"
  [2]=>
  string(150) "Explainable AI aims to make models more interpretable and transparent, ensuring their decision-making processes can be understood and trusted by clini"
  ["short_description"]=>
  string(150) "Explainable AI aims to make models more interpretable and transparent, ensuring their decision-making processes can be understood and trusted by clini"
  [3]=>
  string(171) "Explainable AI aims to make models more interpretable and transparent, ensuring their decision-making processes can be understood and trusted by clinicians and others.&#nl"
  ["description"]=>
  string(171) "Explainable AI aims to make models more interpretable and transparent, ensuring their decision-making processes can be understood and trusted by clinicians and others.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(96) "https://www.healthcareitnews.com/news/rush-toward-ai-healthcare-continues-explainability-crucial"
  ["blog_url"]=>
  string(96) "https://www.healthcareitnews.com/news/rush-toward-ai-healthcare-continues-explainability-crucial"
  [15]=>
  string(19) "2024-08-21 00:24:34"
  ["add_date"]=>
  string(19) "2024-08-21 00:24:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:43"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9327"
  ["article_id"]=>
  string(4) "9327"
  [1]=>
  string(75) "Quick Notes: Medical Device Clearances and Approvals — Aug. 20, 2024"
  ["article_title"]=>
  string(75) "Quick Notes: Medical Device Clearances and Approvals — Aug. 20, 2024"
  [2]=>
  string(153) "&#nl        In this edition of Quick Notes, we cover FDA nods for a new sterilization method for duodenoscopes, an updated device for sleep apnea, a smal"
  ["short_description"]=>
  string(153) "&#nl        In this edition of Quick Notes, we cover FDA nods for a new sterilization method for duodenoscopes, an updated device for sleep apnea, a smal"
  [3]=>
  string(229) "&#nl        In this edition of Quick Notes, we cover FDA nods for a new sterilization method for duodenoscopes, an updated device for sleep apnea, a smaller continuous glucose monitor and a digital therapy for insomnia.&#nl      "
  ["description"]=>
  string(229) "&#nl        In this edition of Quick Notes, we cover FDA nods for a new sterilization method for duodenoscopes, an updated device for sleep apnea, a smaller continuous glucose monitor and a digital therapy for insomnia.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(103) "https://www.fdanews.com/articles/214034-quick-notes-medical-device-clearances-and-approvals-aug-20-2024"
  ["blog_url"]=>
  string(103) "https://www.fdanews.com/articles/214034-quick-notes-medical-device-clearances-and-approvals-aug-20-2024"
  [15]=>
  string(19) "2024-08-21 00:15:59"
  ["add_date"]=>
  string(19) "2024-08-21 00:15:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9328"
  ["article_id"]=>
  string(4) "9328"
  [1]=>
  string(83) "Eli Lilly’s Zepbound Found to Have Additional Clinical Benefits in New Study"
  ["article_title"]=>
  string(83) "Eli Lilly’s Zepbound Found to Have Additional Clinical Benefits in New Study"
  [2]=>
  string(158) "&#nl        A cohort study recently published in JAMA Network Open has found that Eli Lilly’s blockbuster antidiabetic drug Zepbound (tirzepatide) is l"
  ["short_description"]=>
  string(158) "&#nl        A cohort study recently published in JAMA Network Open has found that Eli Lilly’s blockbuster antidiabetic drug Zepbound (tirzepatide) is l"
  [3]=>
  string(336) "&#nl        A cohort study recently published in JAMA Network Open has found that Eli Lilly’s blockbuster antidiabetic drug Zepbound (tirzepatide) is linked to lower risks of major complications compared to GLP-1 receptor agonist (RA) drugs, suggesting additional clinical boons for the highly sought medication.&#nl      "
  ["description"]=>
  string(336) "&#nl        A cohort study recently published in JAMA Network Open has found that Eli Lilly’s blockbuster antidiabetic drug Zepbound (tirzepatide) is linked to lower risks of major complications compared to GLP-1 receptor agonist (RA) drugs, suggesting additional clinical boons for the highly sought medication.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(115) "https://www.fdanews.com/articles/214032-eli-lillys-zepbound-found-to-have-additional-clinical-benefits-in-new-study"
  ["blog_url"]=>
  string(115) "https://www.fdanews.com/articles/214032-eli-lillys-zepbound-found-to-have-additional-clinical-benefits-in-new-study"
  [15]=>
  string(19) "2024-08-20 23:55:25"
  ["add_date"]=>
  string(19) "2024-08-20 23:55:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9329"
  ["article_id"]=>
  string(4) "9329"
  [1]=>
  string(56) "At-Home OTC Syphilis Test Gets FDA De Novo Marketing Nod"
  ["article_title"]=>
  string(56) "At-Home OTC Syphilis Test Gets FDA De Novo Marketing Nod"
  [2]=>
  string(141) "&#nl        The FDA has given marketing authorization for a novel device for at home syphilis testing using a single drop of blood.&#nl      "
  ["short_description"]=>
  string(141) "&#nl        The FDA has given marketing authorization for a novel device for at home syphilis testing using a single drop of blood.&#nl      "
  [3]=>
  string(141) "&#nl        The FDA has given marketing authorization for a novel device for at home syphilis testing using a single drop of blood.&#nl      "
  ["description"]=>
  string(141) "&#nl        The FDA has given marketing authorization for a novel device for at home syphilis testing using a single drop of blood.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(96) "https://www.fdanews.com/articles/214031-at-home-otc-syphilis-test-gets-fda-de-novo-marketing-nod"
  ["blog_url"]=>
  string(96) "https://www.fdanews.com/articles/214031-at-home-otc-syphilis-test-gets-fda-de-novo-marketing-nod"
  [15]=>
  string(19) "2024-08-20 23:45:18"
  ["add_date"]=>
  string(19) "2024-08-20 23:45:18"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9412"
  ["article_id"]=>
  string(4) "9412"
  [1]=>
  string(86) "Gilead's Livdelzi granted accelerated FDA approval for primary biliary cholangitis"
  ["article_title"]=>
  string(86) "Gilead's Livdelzi granted accelerated FDA approval for primary biliary cholangitis"
  [2]=>
  string(150) "Gilead Sciences, Inc. has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the "
  ["short_description"]=>
  string(150) "Gilead Sciences, Inc. has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the "
  [3]=>
  string(261) "Gilead Sciences, Inc. has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC), a rare and chronic autoimmune disease affecting the bile ducts."
  ["description"]=>
  string(261) "Gilead Sciences, Inc. has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC), a rare and chronic autoimmune disease affecting the bile ducts."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(172) "https://www.outsourcing-pharma.com/Article/2024/08/20/accelerated-fda-approval-for-primary-biliary-cholangitis-treatment?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(172) "https://www.outsourcing-pharma.com/Article/2024/08/20/accelerated-fda-approval-for-primary-biliary-cholangitis-treatment?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-08-20 22:45:00"
  ["add_date"]=>
  string(19) "2024-08-20 22:45:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:39"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9413"
  ["article_id"]=>
  string(4) "9413"
  [1]=>
  string(70) "Bavarian Nordic readies 2 million vaccine doses to fight mpox outbreak"
  ["article_title"]=>
  string(70) "Bavarian Nordic readies 2 million vaccine doses to fight mpox outbreak"
  [2]=>
  string(152) "The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organizationâs declaration"
  ["short_description"]=>
  string(152) "The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organizationâs declaration"
  [3]=>
  string(242) "The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organizationâs declaration of mpox as a Public Health Emergency of International Concern (PHEIC) earlier this month."
  ["description"]=>
  string(242) "The Danish company Bavarian Nordic plans to supply up to 2 million vaccine doses this year in response to the World Health Organizationâs declaration of mpox as a Public Health Emergency of International Concern (PHEIC) earlier this month."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(137) "https://www.biopharma-reporter.com/Article/2024/08/20/2m-vaccines-ready-to-fight-mpox?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(137) "https://www.biopharma-reporter.com/Article/2024/08/20/2m-vaccines-ready-to-fight-mpox?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-08-20 22:08:00"
  ["add_date"]=>
  string(19) "2024-08-20 22:08:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:39"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9435"
  ["article_id"]=>
  string(4) "9435"
  [1]=>
  string(85) "Northwestern Medicine integrates DAX Copilot with Epic, seeking workflow efficiencies"
  ["article_title"]=>
  string(85) "Northwestern Medicine integrates DAX Copilot with Epic, seeking workflow efficiencies"
  [2]=>
  string(150) "The health system is already seeing benefits with reductions in clinician burden, its CIO says, and hopes the AI voice tool can broaden patient access"
  ["short_description"]=>
  string(150) "The health system is already seeing benefits with reductions in clinician burden, its CIO says, and hopes the AI voice tool can broaden patient access"
  [3]=>
  string(188) "The health system is already seeing benefits with reductions in clinician burden, its CIO says, and hopes the AI voice tool can broaden patient access while boosting cost efficiencies.&#nl"
  ["description"]=>
  string(188) "The health system is already seeing benefits with reductions in clinician burden, its CIO says, and hopes the AI voice tool can broaden patient access while boosting cost efficiencies.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(117) "https://www.healthcareitnews.com/news/northwestern-medicine-integrates-dax-copilot-epic-seeking-workflow-efficiencies"
  ["blog_url"]=>
  string(117) "https://www.healthcareitnews.com/news/northwestern-medicine-integrates-dax-copilot-epic-seeking-workflow-efficiencies"
  [15]=>
  string(19) "2024-08-20 21:55:11"
  ["add_date"]=>
  string(19) "2024-08-20 21:55:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:43"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9530"
  ["article_id"]=>
  string(4) "9530"
  [1]=>
  string(78) "FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions"
  ["article_title"]=>
  string(78) "FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions"
  [2]=>
  string(150) "Two months after placing a partial hold on a phase 1 clinical trial evaluating an antibody-drug conjugate (ADC) in cancer patients, the FDA is allowin"
  ["short_description"]=>
  string(150) "Two months after placing a partial hold on a phase 1 clinical trial evaluating an antibody-drug conjugate (ADC) in cancer patients, the FDA is allowin"
  [3]=>
  string(211) "Two months after placing a partial hold on a phase 1 clinical trial evaluating an antibody-drug conjugate (ADC) in cancer patients, the FDA is allowing the study to proceed with the lower doses of the treatment."
  ["description"]=>
  string(211) "Two months after placing a partial hold on a phase 1 clinical trial evaluating an antibody-drug conjugate (ADC) in cancer patients, the FDA is allowing the study to proceed with the lower doses of the treatment."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(157) "https://www.biopharma-reporter.com/Article/2024/08/20/fda-lifts-hold-on-biontech-and-medilink-s-adc-trial?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(157) "https://www.biopharma-reporter.com/Article/2024/08/20/fda-lifts-hold-on-biontech-and-medilink-s-adc-trial?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-08-20 21:35:00"
  ["add_date"]=>
  string(19) "2024-08-20 21:35:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:26:38"
  ["create_at"]=>
  string(19) "2024-08-24 15:26:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9366"
  ["article_id"]=>
  string(4) "9366"
  [1]=>
  string(115) "SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System"
  ["article_title"]=>
  string(115) "SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System"
  [2]=>
  string(152) "SANTA CLARA, Calif., Aug.  20, 2024  (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to pr"
  ["short_description"]=>
  string(152) "SANTA CLARA, Calif., Aug.  20, 2024  (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to pr"
  [3]=>
  string(561) "
SANTA CLARA, Calif., Aug.  20, 2024  (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion.
"
  ["description"]=>
  string(561) "
SANTA CLARA, Calif., Aug.  20, 2024  (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(184) "https://www.globenewswire.com/news-release/2024/08/20/2932785/0/en/SI-BONE-Inc-Receives-510-k-Clearance-and-FDA-Breakthrough-Device-Designation-for-Pelvic-Fracture-Fixation-System.html"
  ["blog_url"]=>
  string(184) "https://www.globenewswire.com/news-release/2024/08/20/2932785/0/en/SI-BONE-Inc-Receives-510-k-Clearance-and-FDA-Breakthrough-Device-Designation-for-Pelvic-Fracture-Fixation-System.html"
  [15]=>
  string(19) "2024-08-20 20:30:00"
  ["add_date"]=>
  string(19) "2024-08-20 20:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:22"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9389"
  ["article_id"]=>
  string(4) "9389"
  [1]=>
  string(47) "MEDICAL JAPAN TOKYO introduces news trade fairs"
  ["article_title"]=>
  string(47) "MEDICAL JAPAN TOKYO introduces news trade fairs"
  [2]=>
  string(150) "MEDICAL JAPAN TOKYO returns to Makuhari Messe from 9-11th October, covering everything related to the medical, elderly care, pharmacy, and healthcare "
  ["short_description"]=>
  string(150) "MEDICAL JAPAN TOKYO returns to Makuhari Messe from 9-11th October, covering everything related to the medical, elderly care, pharmacy, and healthcare "
  [3]=>
  string(206) "MEDICAL JAPAN TOKYO returns to Makuhari Messe from 9-11th October, covering everything related to the medical, elderly care, pharmacy, and healthcare sectors and introducing more than seven new trade fairs."
  ["description"]=>
  string(206) "MEDICAL JAPAN TOKYO returns to Makuhari Messe from 9-11th October, covering everything related to the medical, elderly care, pharmacy, and healthcare sectors and introducing more than seven new trade fairs."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(118) "https://www.medicalplasticsnews.com/news/latest-medical-plastics-news/medical-japan-tokyo-introduces-news-trade-fairs/"
  ["blog_url"]=>
  string(118) "https://www.medicalplasticsnews.com/news/latest-medical-plastics-news/medical-japan-tokyo-introduces-news-trade-fairs/"
  [15]=>
  string(19) "2024-08-20 20:30:00"
  ["add_date"]=>
  string(19) "2024-08-20 20:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:32"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9317"
  ["article_id"]=>
  string(4) "9317"
  [1]=>
  string(79) "Theramex’s Eladynos recommended by NICE for post-menopausal bone disease"
  ["article_title"]=>
  string(79) "Theramex’s Eladynos recommended by NICE for post-menopausal bone disease"
  [2]=>
  string(119) "Osteoporosis currently affects 3.8 million people in the UK, particularly impacting older women after menopause&#nl&#nl"
  ["short_description"]=>
  string(119) "Osteoporosis currently affects 3.8 million people in the UK, particularly impacting older women after menopause&#nl&#nl"
  [3]=>
  string(261) "
Osteoporosis currently affects 3.8 million people in the UK, particularly impacting older women after menopause
&#nl
&#nl"
  ["description"]=>
  string(261) "
Osteoporosis currently affects 3.8 million people in the UK, particularly impacting older women after menopause
&#nl
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(101) "https://pharmatimes.com/news/theramexs-eladynos-recommended-by-nice-for-post-menopausal-bone-disease/"
  ["blog_url"]=>
  string(101) "https://pharmatimes.com/news/theramexs-eladynos-recommended-by-nice-for-post-menopausal-bone-disease/"
  [15]=>
  string(19) "2024-08-20 19:50:55"
  ["add_date"]=>
  string(19) "2024-08-20 19:50:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:00"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:00"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}